Probiotics have two separate evidence bases and they point in different directions. For eczema that already exists, a 2018 Cochrane review of 39 trials found little or no difference in how people rated their own symptoms (Makrgeorgou et al, 2018). For preventing eczema in infants at high risk of allergy, a World Allergy Organization panel found enough signal to issue three conditional suggestions (Fiocchi et al, 2015). Treatment and prevention are different questions with different answers.
What the treatment trials measured
The 2018 Cochrane review pooled 39 randomised controlled trials and 2,599 participants. Two outcomes carry the answer.
The first is what participants and parents reported themselves. On a symptom scale from 0 to 20, severity was 0.44 points lower after probiotic treatment, with a confidence interval running from 1.22 points lower to 0.33 points higher (13 trials, 754 participants, moderate-quality evidence). The interval crosses zero: these trials cannot separate the effect from no effect.
The second is what investigators scored. A combined score of investigator-rated severity plus the participant's own scoring of itch and sleep loss was 3.91 points lower (95% CI 5.86 to 1.96 points lower, 24 trials, 1,596 participants, low-quality evidence). That is a measurable difference, but the review notes the minimum clinically important difference for SCORAD "has been estimated to be 8.7 points". The effect is under half the smallest change a clinician would call meaningful.
Who was studied matters. Participants ran from the first year of life to 55 years, 33 studies assessed children up to 18, and only six assessed adults. The review's conclusion is blunt: "use of probiotics for the treatment of eczema is currently not evidence-based".
On harms it found "no evidence to show that probiotics make a difference in the risk of adverse events during active treatment" (RR 1.54, 95% CI 0.90 to 2.63, seven trials, 402 participants, low-quality evidence). The interval spans no difference and a modest increase, across 402 people.
Prevention is a different question
The World Allergy Organization and McMaster University panel worked from a systematic review and meta-analysis by Cuello-Garcia and colleagues (Cuello-Garcia et al, 2015), then issued three recommendations, each conditional and each resting on very low certainty evidence: probiotics in pregnant women at high risk of allergy in their children, in women breastfeeding infants at high risk, and in those infants themselves.
High risk carries a specific definition in that guideline: a "biological parent or sibling with existing or history of allergic rhinitis, asthma, eczema, or food allergy". The eczema effects the panel reported were a risk ratio of 0.72 (95% CI 0.61 to 0.85) for probiotics in pregnancy, 0.61 during breastfeeding, and 0.81 (95% CI 0.70 to 0.94) given to infants.
Two limits sit on those numbers. The benefit is specific to eczema, since "there is lack of evidence that probiotics prevent any other allergy", asthma and food allergy included. And the window is pregnancy, breastfeeding and infancy. None of it carries across to an adult managing eczema they already have. Food allergy in an infant with eczema is a separate prevention question with its own UK guidance, covered in baby eczema and food allergy.
Why no one can name the strain or the dose
The Cochrane trials "identified no standard dose". Concentrations ran from 10 million bacteria per gram of formula up to 78 billion a day, and treatment lasted from four weeks to six months. The organisms were Lactobacillus and Bifidobacterium species, given alone or in combination, with or without prebiotics.
The guideline panel could not sort the effect by organism either: "it was also not possible to analyze the effects of individual probiotic species and/or strains", and a lack of observed difference between probiotics "does not imply that such a difference does not exist."
A capsule naming a strain and a colony-forming-unit count is describing its contents, not reproducing a tested protocol. The trials never converged on one to reproduce.
What the gut-skin axis actually describes
The mechanism behind the prevention trials is specific. Gut bacteria ferment non-digestible carbohydrates into short-chain fatty acids, mainly acetic, propionic and butyric acid (Rios-Carlos et al, 2024). Butyrate from commensal microbes "induces functional colonic and follicular Treg cells, at least in part through epigenetic upregulation of related genes to Treg differentiation, such as the Foxp3 gene", and those regulatory T cells "might acquire the ability to migrate from gut-associated lymphoid tissues to the skin". That is a route from what the gut ferments to how the skin's immune response is regulated.
Composition differs in atopic dermatitis as well. Comparisons with healthy controls show a "common signature of decreased bacterial diversity", alongside a deficiency of Bifidobacterium, Enterococcus, Bacteroides and Ruminococcus. In animal models of atopic dermatitis with a damaged epidermal barrier, supplementing with inulin or butyrate produced less severe disease and a marked reduction in transepidermal water loss, the same measure used to assess a leaking skin barrier in people. Those are results from animal models, not human trials.
A plausible mechanism is why the trials ran. It does not replace what they found.
Where the evidence leaves a decision
NICE guidance for atopic eczema in under 12s tells families that the effectiveness and safety of homeopathy, herbal medicine, massage and food supplements "have not yet adequately been assessed in clinical trials", and that emollients remain the basis of management, used even when the skin is clear (NICE, CG57).
The supported position is narrow: a conditional, low-certainty case during pregnancy, breastfeeding and infancy in high-risk families. It does not extend to treating an established flare, and the adult evidence is six trials out of 39.
Learning anything from a supplement means changing one variable at a time and recording what happens. The four-week food diary method applies to a capsule as readily as to a food: log severity, itch and sleep daily, then compare your five worst days against your five best. Trials in the Cochrane review ran from four weeks to six months, so a fortnight of use answers nothing.
The same method covers the dietary questions next to this one: histamine, and the structured elimination diet that confirms or rules out a suspected food trigger rather than avoiding it indefinitely.
References
- Makrgeorgou A, Leonardi-Bee J, Bath-Hextall FJ, Murrell DF, Tang MLK, Roberts A, Boyle RJ. Probiotics for treating eczema. Cochrane Database of Systematic Reviews, 2018, issue 11, CD006135. https://pmc.ncbi.nlm.nih.gov/articles/PMC6517242/
- Fiocchi A, Pawankar R, Cuello-Garcia C, et al. World Allergy Organization-McMaster University Guidelines for Allergic Disease Prevention (GLAD-P): Probiotics. World Allergy Organization Journal, 2015, 8:4. https://pmc.ncbi.nlm.nih.gov/articles/PMC4307749/
- Cuello-Garcia CA, Brozek JL, Fiocchi A, et al. Probiotics for the prevention of allergy: a systematic review and meta-analysis of randomized controlled trials. Journal of Allergy and Clinical Immunology, 2015, 136:952-961. https://doi.org/10.1016/j.jaci.2015.04.031
- Rios-Carlos M, Cervantes-Garcia D, Cordova-Davalos LE, Bermudez-Humaran LG, Salinas E. Unraveling the gut-skin axis in atopic dermatitis: exploiting insights for therapeutic strategies. Gut Microbes, 2024, 16:2430420. https://pmc.ncbi.nlm.nih.gov/articles/PMC11610564/
- National Institute for Health and Care Excellence. Atopic eczema in under 12s: diagnosis and management. NICE Clinical Guideline 57. https://www.ncbi.nlm.nih.gov/books/NBK571009/